c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas-Reference-Cited by-同舟云学术

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

Published:2018-12 Issue:12 Volume:13 Page:1962-1967
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Mignard Xavier^ORCID,Ruppert Anne-Marie,Antoine Martine,Vasseur Julie,Girard Nicolas,Mazières Julien,Moro-Sibilot Denis,Fallet Vincent,Rabbe Nathalie,Thivolet-Bejui Françoise,Rouquette Isabelle,Lantuejoul Sylvie,Cortot Alexis,Saffroy Raphaël,Cadranel Jacques,Lemoine Antoinette,Wislez Marie

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Exon 14 deleted MET receptor as a new biomarker and target in cancers;Cortot;J Natl Cancer Inst,2017

2. Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients;Cappuzzo;J Clin Oncol,2009

3. MET Amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis;Tong;Clin Cancer Res,2016

4. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Discov,2015

5. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non–small cell lung cancer patient with de novo MET amplification;Ou;J Thorac Oncol,2011

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reproducibility of c-Met Immunohistochemical Scoring (Clone SP44) for Non–Small Cell Lung Cancer Using Conventional Light Microscopy and Whole Slide Imaging;American Journal of Surgical Pathology;2024-07-08

2. Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer;World Journal of Gastrointestinal Surgery;2024-05-27

3. Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation;Modern Pathology;2024-04

4. Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review;Translational Lung Cancer Research;2024-03

5. Targeting MET in NSCLC: An Ever-Expanding Territory;JTO Clinical and Research Reports;2024-02